366 related articles for article (PubMed ID: 15990426)
1. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease.
Brodaty H; Corey-Bloom J; Potocnik FC; Truyen L; Gold M; Damaraju CR
Dement Geriatr Cogn Disord; 2005; 20(2-3):120-32. PubMed ID: 15990426
[TBL] [Abstract][Full Text] [Related]
2. Galantamine treatment of vascular dementia: a randomized trial.
Auchus AP; Brashear HR; Salloway S; Korczyn AD; De Deyn PP; Gassmann-Mayer C;
Neurology; 2007 Jul; 69(5):448-58. PubMed ID: 17664404
[TBL] [Abstract][Full Text] [Related]
3. Two galantamine titration regimens in patients switched from donepezil.
Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
[TBL] [Abstract][Full Text] [Related]
4. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
5. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
[TBL] [Abstract][Full Text] [Related]
6. Efficacy study of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients: a slow-titration regimen.
Thavichachart N; Phanthumchinda K; Chankrachang S; Praditsuwan R; Nidhinandana S; Senanarong V; Poungvarin N
Int J Clin Pract; 2006 May; 60(5):533-40. PubMed ID: 16700849
[TBL] [Abstract][Full Text] [Related]
7. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
[TBL] [Abstract][Full Text] [Related]
8. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
9. Effects of galantamine in patients with mild Alzheimer's disease.
Orgogozo JM; Small GW; Hammond G; Van Baelen B; Schwalen S
Curr Med Res Opin; 2004 Nov; 20(11):1815-20. PubMed ID: 15537482
[TBL] [Abstract][Full Text] [Related]
10. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study.
Dunbar F; Zhu Y; Brashear HR
Clin Ther; 2006 Mar; 28(3):365-72. PubMed ID: 16750451
[TBL] [Abstract][Full Text] [Related]
11. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
[TBL] [Abstract][Full Text] [Related]
12. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
13. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial.
Erkinjuntti T; Kurz A; Gauthier S; Bullock R; Lilienfeld S; Damaraju CV
Lancet; 2002 Apr; 359(9314):1283-90. PubMed ID: 11965273
[TBL] [Abstract][Full Text] [Related]
15. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
[TBL] [Abstract][Full Text] [Related]
16. Galantamine for Alzheimer's disease and mild cognitive impairment.
Loy C; Schneider L
Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD001747. PubMed ID: 16437436
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of galantamine in possible Alzheimer's disease with or without cerebrovascular disease and vascular dementia in Thai patients.
Senanarong V; Poungvarin N; Phanthumchinda K; Thavichachart N; Chankrachang S; Praditsuwan R; Nidhinandana S
J Med Assoc Thai; 2009 Mar; 92 Suppl 2():S12-8. PubMed ID: 19562980
[TBL] [Abstract][Full Text] [Related]
18. A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.
Dubois B; McKeith I; Orgogozo JM; Collins O; Meulien D
Int J Geriatr Psychiatry; 1999 Nov; 14(11):973-82. PubMed ID: 10556869
[TBL] [Abstract][Full Text] [Related]
19. Galantamine for Alzheimer's disease.
Olin J; Schneider L
Cochrane Database Syst Rev; 2002; (3):CD001747. PubMed ID: 12137632
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
Sevigny JJ; Ryan JM; van Dyck CH; Peng Y; Lines CR; Nessly ML;
Neurology; 2008 Nov; 71(21):1702-8. PubMed ID: 19015485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
